WALTHAM, Mass., June 1 Millennium Research Group's (MRG's) Cardiovascular Division Manager, Stephanie LaBelle, is available to offer extensive expertise on today's announcement that Covidien PLC will acquire ev3 for $2.6 billion.
"Covidien's announcement of its plans to acquire ev3 reflects the company's ongoing efforts to maximize its position in the cardiovascular device market," says Ms. LaBelle. "In particular, it will secure Covidien's position in the market for the treatment of peripheral arterial disease, which is a nice complement to previous acquisitions--VNUS Medical Technologies and Bacchus Vascular--that were focused on the treatment of venous disease."
Ms. LaBelle is available to comment on:
MRG's global vascular expertise covers devices used in the treatment of peripheral artery disease, chronic venous insufficiency, venous thromboembolism, intracranial aneurysms, neurovascular abnormalities, and more. MRG is the global authority on medical technology market intelligence.
To arrange an interview with Ms. LaBelle, please contact Amy Krohn at 416-364-7776 ext. 101 or email@example.com.
About Millennium Research Group
Millennium Research Group (www.MRG.net), a Decision Resources, Inc. company (www.DecisionResourcesInc.com), is the global authority on medical technology market intelligence and the leading provider of strategic information to the healthcare sector. The company provides specialized industry expertise through multiclient market research, ongoing Marketrack(TM) projects, customer loyalty tracking, facility-level procedure forecasting, and customized solutions.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
-- How ev3's product lines complement Covidien's current device portfolio
SOURCE Millennium Research Group